跳至主要内容
临床试验/NCT01265173
NCT01265173已完成4 期

Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis

Korea University2 个研究点 分布在 1 个国家目标入组 261 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
261
试验地点
2
主要终点
Infection resolution rates within 5 days of treatment

研究概览

简要总结

Spontaneous bacterial peritonitis (SBP) is one of the most serious complications of liver cirrhosis. Mainstay of treatment for SBP is use of proper antibiotics. Although, several antibiotics including cefotaxime, ceftriaxone, or ciprofloxacin are being used, it is unclear which drug is most effective. Our aim of study is to compare the efficacy of the three current antibiotics for the treatment of SBP in patients with liver cirrhosis.

The primary hypothesis is that the efficacy of all the antibiotics will not significantly different. This is non-inferiority trial.

详细描述

Spontaneous bacterial peritonitis (SBP) is one of the most serious complications of liver cirrhosis. Mainstay of treatment for SBP is use of proper antibiotics. Although, several antibiotics including cefotaxime, ceftriaxone, or ciprofloxacin are being used, it is unclear which drug is most effective. Our aim of study is to compare the efficacy of the three current antibiotics for the treatment of SBP in patients with liver cirrhosis.

The primary hypothesis is that the efficacy of all the antibiotics will not significantly different. The expected success rates (infection resolution rates) are 83%, 87%, and 78% for cefotaxime, ceftriaxone, and ciprofloxacin. This is non-inferiority trial. The level of significance is 5%. The power of this stuy is 80%. Non-inferiority margin is 15%. Therefore 87 patients for each group are needed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Liver cirrhosis patients with ascites
  • Ascitic fluid PMN cell count >250/mm3
  • Age: 16~70 years old

排除标准

  • Allergic to 3rd generation cephalosporin or quinolone
  • Antibiotics within 2 weeks
  • Open abdominal surgery within 4 weeks
  • Evidence of 2ndary peritonitis, intrabdominal hemorrhage, pancreatitis, Tb peritonitis, or peritoneal carcinomatosis
  • HCC with portal vein thrombosis
  • Pregnant woman
  • HIV positive

研究组 & 干预措施

Cefotaxime

Active Comparator

iv 2G q 8hrs for general, dose titration if needed (eg.CKD)

干预措施: Cefotaxime (Drug)

Ceftriaxone

Experimental

iv 2G q 24hrs

干预措施: Ceftriaxone (Drug)

Ciprofloxacine

Experimental

iv 400mg q 12hrs for general, dose titration if needed (eg.CKD)

干预措施: Ciprofloxacin (Drug)

结局指标

主要结局

Infection resolution rates within 5 days of treatment

时间窗: 5 days (120 hours)

PMN \< 250/mm3 from ascitic fluid

次要结局

  • Mortality & recurrence rates within 1 month(1 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Soon Ho Um

Professor

Korea University

研究点 (2)

Loading locations...

相似试验